Shedir Pharma Group Past Earnings Performance
Past criteria checks 2/6
Shedir Pharma Group has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 6% per year. Shedir Pharma Group's return on equity is 16.2%, and it has net margins of 9.8%.
Key information
13.4%
Earnings growth rate
17.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 6.0% |
| Return on equity | 16.2% |
| Net Margin | 9.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05
Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Recent updates
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?
Apr 06What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 30
Revenue & Expenses Breakdown
How Shedir Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 61 | 6 | 6 | 0 |
| 31 Mar 24 | 60 | 6 | 6 | 0 |
| 31 Dec 23 | 59 | 6 | 6 | 0 |
| 30 Sep 23 | 59 | 6 | 6 | 0 |
| 30 Jun 23 | 58 | 6 | 5 | 0 |
| 31 Mar 23 | 56 | 6 | 5 | 0 |
| 31 Dec 22 | 53 | 6 | 5 | 0 |
| 30 Sep 22 | 51 | 5 | 5 | 0 |
| 30 Jun 22 | 49 | 4 | 5 | 0 |
| 31 Mar 22 | 47 | 4 | 5 | 0 |
| 31 Dec 21 | 45 | 4 | 4 | 0 |
| 30 Sep 21 | 44 | 4 | 4 | 0 |
| 30 Jun 21 | 43 | 3 | 4 | 0 |
| 31 Mar 21 | 43 | 4 | 4 | 0 |
| 31 Dec 20 | 43 | 4 | 4 | 0 |
| 30 Sep 20 | 44 | 3 | 5 | 0 |
| 30 Jun 20 | 45 | 3 | 5 | 0 |
| 31 Mar 20 | 47 | 3 | 5 | 0 |
| 31 Dec 19 | 51 | 3 | 5 | 0 |
| 30 Sep 19 | 50 | 4 | 5 | 0 |
| 30 Jun 19 | 49 | 5 | 5 | 0 |
| 31 Mar 19 | 49 | 6 | 5 | 0 |
| 31 Dec 18 | 47 | 7 | 5 | 0 |
| 31 Dec 17 | 40 | 3 | 4 | 0 |
Quality Earnings: SHE has high quality earnings.
Growing Profit Margin: SHE's current net profit margins (9.8%) are lower than last year (10.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHE's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: SHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SHE had negative earnings growth (-2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.5%).
Return on Equity
High ROE: SHE's Return on Equity (16.2%) is considered low.